Ellington Management Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Ellington Management Group’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,000	Closed	-$149K	–	987
2018 Q1	$149K	Buy	+20,000	New	+$133K	0.01%	763
2017 Q1	–	Sell	-13,000	Closed	-$112K	–	941
2016 Q4	$112K	Sell	13,000 -54,200	-81%	-$401K	0.02%	493
2016 Q3	$425K	Buy	+67,200	New	+$406K	0.12%	336
2015 Q4	–	Sell	-20,146	Closed	-$115K	–	909
2015 Q3	$115K	Buy	+20,146	New	+$155K	0.03%	650
2015 Q2	–	Sell	-64,400	Closed	-$385K	–	970
2015 Q1	$385K	Buy	64,400 +11,800	+22%	+$74.3K	0.08%	378
2014 Q4	$398K	Buy	+52,600	New	+$315K	0.13%	255

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Ellington Management Group's PGNX Position: Q2 2018 in Review

Ellington Management Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2018, closing a stake of 20,000 shares — an estimated $149K sold.

Ellington Management Group first reported a position in PGNX in Q4 2014 and held it in 6 quarters. The position peaked at $425K in Q3 2016. 155 funds tracked by Wall St. Rank hold PGNX as of Q2 2018.

Ellington Management Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
Ellington Management Group sold 20,000 Progenics Pharmaceuticals Inc shares in Q2 2018, an estimated $149K.
Ellington Management Group first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 6 quarters.
Ellington Management Group's Progenics Pharmaceuticals Inc position peaked at $425K in Q3 2016.
155 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.